A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

HomeDoctor Raises €3,7m Series A Funding Led by Cogito Capital Partners

What To Know

  • HomeDoctor will use the investment to continue the growth of its operations in Poland, building its team and capacity in order to further expand geographically and build strategic partnerships aimed at scaling-up the Company's offering and market reach.
  • For home-visits business, the Company uses geo-location technology, to ensure that the nearest available doctor is dispatched to a patient, which allows for the delivery of a home visit within 1 hour of wait time.

October 1, 2020

HomeDoctor is a Warsaw and Amsterdam-based digital healthcare provider.

HomeDoctor announced a €3,7m Series A funding round led by Cogito Capital Partners with participation from the Company’s founders. HomeDoctor, founded in 2016, is a leader in the Polish market in providing online medical consultations and delivery of healthcare services to patients’ homes. The Company is operating as a b2b2c and a b2c medical services platform that enables delivery of both, online and phone consultations (telemedicine channel) and booking a doctor appointment (home visit).

HomeDoctor is also a key partner for the largest medical centers and insurers in Poland. They developed an effective and patient-centric healthcare model that combines complementary digital and physical consultations. HomeDoctor’s services are available online as well as through a dedicated mobile app (connecting doctors and patients). For home-visits business, the Company uses geo-location technology, to ensure that the nearest available doctor is dispatched to a patient, which allows for the delivery of a home visit within 1 hour of wait time. This feature, combined with over 200 GPs dedicated to home-visits, gives HomeDoctor a unique competitive advantage and a clear leadership position in Poland. The Company works with over 350 doctors (GPs as well as 16 different specializations) who call on patients across Poland. With the onset of the COVID-19 pandemic, the Company recorded an unprecedented growth in demand, especially in teleconsultations.

Also, the Q3 2020 data shows a dynamic growth in the number of home visits. This model gives the Company a competitive advantage and enables for patient-centric innovations. HomeDoctor’s ambitious growth strategy focuses on further product development – telemedicine consultation service (telco/video), both in the b2b and b2b2c models, expansion of home visits, and an integrated online pharmacy as well as tailored offerings for enterprise customers. HomeDoctor will use the investment to continue the growth of its operations in Poland, building its team and capacity in order to further expand geographically and build strategic partnerships aimed at scaling-up the Company’s offering and market reach. The Company plans on expanding its services to other European countries, building on growing adoption of telemedicine, regulatory changes, and developments in digital healthcare across Europe. Recent regulatory and reimbursement changes allow digital healthcare providers to be part of the publicly funded healthcare systems and thus increase access to highly competent and experienced medical professionals in the European countries.

The team behind HomeDoctor comprises of serial entrepreneurs and business executives, who have successfully built and scaled both enterprise and consumer-focused businesses. Szymon Horaczuk, the Founder and CEO of HomeDoctor said:

“Home Doctor’s mission is to transform the traditional healthcare model challenged by accessibility issues and deliver healthcare services to consumers in a seamless, patient-centric way. We are delighted to have Cogito on board, to support our plans and strengthen our capacity to execute our ambitious growth and expansion strategy”. Sylwester Janik, General Partner at Cogito said: “We are excited to partner with Szymon and his team to support HomeDoctor’s product and market expansion plans. The Company’s offering meets patients’ needs and preferences for affordable and accessible healthcare services, conveniently delivered online and directly to their homes, and is a game-changer in the healthcare industry”.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

With this new investment partnership, E Tech Group expects to accelerate organic growth and acquisition to become a top system integrator in North America.
The investment will allow ROM InWest to further distribute its fall detection product globally.
Nawal Ouzren, Sensorion’s Chief Executive Officer, said: “We are thrilled to announce another successful capital raise, securing an additional EUR 15 million to accommodate interest expressed by certain existing investors. This builds on the earlier EUR 50 million financing announced in February 2024, adding up to a total of EUR 100 million raised in less than 9 months. With this new financing, we are well-positioned to accelerate our gene therapy programs, including the progression of SENS-501 through its Phase 1/2 clinical study, Audiogene, and the advancement of our second program, GJB2-GT, towards Clinical Trial Applications submission in H1 2025. The capital increase enables the Company to finance its activities until the end of 2025. We remain deeply thankful for the ongoing support of our shareholders and partners as we strive to make a meaningful difference in the lives of those affected by hearing loss disorders.”
Strategic Investor, Osang Healthcare will partner with Kryptos Biotechnologies for the manufacturing and distribution of the product along with financing.
Proceeds from the financing will advance Obsidian’s lead engineered tumor-infiltrating lymphocyte (TIL) program, OBX-115, in its ongoing trials for patients with melanoma and non-small cell lung cancer (NSCLC). Obsidian Therapeutics is focused on enrolling patients and reaching key clinical and regulatory milestones, as well as manufacturing scale-up ahead of pivotal trial readiness.

By using this website you agree to accept Medical Device News Magazine Privacy Policy